Cargando…

Early Insights from Commercialization of Gene Therapies in Europe

Detalles Bibliográficos
Autores principales: Touchot, Nicolas, Flume, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333067/
https://www.ncbi.nlm.nih.gov/pubmed/28218692
http://dx.doi.org/10.3390/genes8020078
_version_ 1782511654621151232
author Touchot, Nicolas
Flume, Mathias
author_facet Touchot, Nicolas
Flume, Mathias
author_sort Touchot, Nicolas
collection PubMed
description
format Online
Article
Text
id pubmed-5333067
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53330672017-03-13 Early Insights from Commercialization of Gene Therapies in Europe Touchot, Nicolas Flume, Mathias Genes (Basel) Communication MDPI 2017-02-17 /pmc/articles/PMC5333067/ /pubmed/28218692 http://dx.doi.org/10.3390/genes8020078 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Touchot, Nicolas
Flume, Mathias
Early Insights from Commercialization of Gene Therapies in Europe
title Early Insights from Commercialization of Gene Therapies in Europe
title_full Early Insights from Commercialization of Gene Therapies in Europe
title_fullStr Early Insights from Commercialization of Gene Therapies in Europe
title_full_unstemmed Early Insights from Commercialization of Gene Therapies in Europe
title_short Early Insights from Commercialization of Gene Therapies in Europe
title_sort early insights from commercialization of gene therapies in europe
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333067/
https://www.ncbi.nlm.nih.gov/pubmed/28218692
http://dx.doi.org/10.3390/genes8020078
work_keys_str_mv AT touchotnicolas earlyinsightsfromcommercializationofgenetherapiesineurope
AT flumemathias earlyinsightsfromcommercializationofgenetherapiesineurope